tiprankstipranks
Immunicum AB (DE:1YG0)
FRANKFURT:1YG0

Immunicum AB (1YG0) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Immunicum AB has a market cap or net worth of €40.56M. The enterprise value is €322.08.
Market Cap€40.56M
Enterprise Value€322.08

Share Statistics

Immunicum AB has 64,784,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64,784,580
Owned by Insiders
Owned by Institutions

Financial Efficiency

Immunicum AB’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -19.91%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-19.91%
Return on Capital Employed (ROCE)-0.20
Revenue Per Employee0.00
Profits Per Employee-5.96M
Employee Count19
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Immunicum AB is ―. Immunicum AB’s PEG ratio is 0.14.
PE Ratio
PS Ratio0.00
PB Ratio0.50
Price to Fair Value0.50
Price to FCF-3.57
Price to Operating Cash Flow-6.05
PEG Ratio0.14

Income Statement

In the last 12 months, Immunicum AB had revenue of 0.00 and earned -113.26M in profits. Earnings per share was -2.17.
Revenue0.00
Gross Profit-6.29M
Operating Income-120.26M
Pretax Income-113.26M
Net Income-113.26M
EBITDA-113.97M
Earnings Per Share (EPS)-2.17

Cash Flow

In the last 12 months, operating cash flow was -73.93M and capital expenditures -617.00K, giving a free cash flow of -74.54M billion.
Operating Cash Flow-73.93M
Free Cash Flow-74.54M
Free Cash Flow per Share-1.15

Dividends & Yields

Immunicum AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.20
52-Week Price Change-6.32%
50-Day Moving Average0.57
200-Day Moving Average0.48
Relative Strength Index (RSI)56.76
Average Volume (3m)16.00

Important Dates

Immunicum AB upcoming earnings date is Nov 11, 2026, Before Open (Confirmed).
Last Earnings DateAug 20, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date

Financial Position

Immunicum AB as a current ratio of 2.70, with Debt / Equity ratio of 3.29%
Current Ratio2.70
Quick Ratio2.70
Debt to Market Cap<0.01
Net Debt to EBITDA0.40
Interest Coverage Ratio-36.63

Taxes

In the past 12 months, Immunicum AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Immunicum AB EV to EBITDA ratio is -2.16, with an EV/FCF ratio of -3.01.
EV to Sales0.00
EV to EBITDA-2.16
EV to Free Cash Flow-3.01
EV to Operating Cash Flow-3.02

Balance Sheet

Immunicum AB has €59.88M in cash and marketable securities with €17.93M in debt, giving a net cash position of €41.95M billion.
Cash & Marketable Securities€59.88M
Total Debt€17.93M
Net Cash€41.95M
Net Cash Per Share€0.65
Tangible Book Value Per Share€1.01

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Immunicum AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast13.10%

Scores

Smart ScoreN/A
AI Score